

Colgate-Palmolive vs Kimberly-Clark
Colgate-Palmolive defends global oral care and personal hygiene franchises with pricing power that's proven resilient through multiple inflationary cycles while Kimberly-Clark sells diapers, tissues, and professional hygiene products to consumers who buy out of necessity but will trade down to private label when budgets tighten. Both are consumer staples companies leaning on brand strength and distribution scale to hold shelf space in a world where retailer private label competition keeps intensifying. Colgate-Palmolive vs Kimberly-Clark reveals where premium pricing holds, where private label substitution erodes volume, and which franchise's organic revenue growth and margin trajectory looks more resilient into the next cost cycle.
Colgate-Palmolive defends global oral care and personal hygiene franchises with pricing power that's proven resilient through multiple inflationary cycles while Kimberly-Clark sells diapers, tissues, ...
Why It's Moving

Colgate-Palmolive stock faces technical headwinds as analysts signal caution amid execution risks
- Technical analysis reveals bearish signals including negative MACD and Awesome Oscillator readings, with the stock trading within a falling trend and positioned for potential weakness over the coming weeks
- Analysts cite execution risks surrounding the company's 3-year strategic growth and productivity program, with average price targets implying modest downside of approximately 1.26% from current levels
- August 2026 forecasts project potential weakness with predicted returns of negative 14.27%, though April historically shows strong seasonal strength with a 78.57% probability of positive returns, creating near-term volatility

Kimberly-Clark Stock Faces Mixed Analyst Outlook as UBS Trims Price Target Amid Revenue Headwinds
- UBS Group cut its price target to $105 from $110 with a maintained neutral rating, joining multiple brokerages in trimming forecasts recently as revenue declined 0.6% year-over-year
- The company beat earnings estimates with Q1 EPS of $1.86 but posted a revenue miss, raising concerns about demand headwinds offset by operational efficiency
- Analyst consensus remains split with 3 buys, 11 holds, and 1 sell among recent ratings, though the stock's high debt-to-equity ratio of 3.97 is weighing on investor sentiment

Colgate-Palmolive stock faces technical headwinds as analysts signal caution amid execution risks
- Technical analysis reveals bearish signals including negative MACD and Awesome Oscillator readings, with the stock trading within a falling trend and positioned for potential weakness over the coming weeks
- Analysts cite execution risks surrounding the company's 3-year strategic growth and productivity program, with average price targets implying modest downside of approximately 1.26% from current levels
- August 2026 forecasts project potential weakness with predicted returns of negative 14.27%, though April historically shows strong seasonal strength with a 78.57% probability of positive returns, creating near-term volatility

Kimberly-Clark Stock Faces Mixed Analyst Outlook as UBS Trims Price Target Amid Revenue Headwinds
- UBS Group cut its price target to $105 from $110 with a maintained neutral rating, joining multiple brokerages in trimming forecasts recently as revenue declined 0.6% year-over-year
- The company beat earnings estimates with Q1 EPS of $1.86 but posted a revenue miss, raising concerns about demand headwinds offset by operational efficiency
- Analyst consensus remains split with 3 buys, 11 holds, and 1 sell among recent ratings, though the stock's high debt-to-equity ratio of 3.97 is weighing on investor sentiment
Investment Analysis
Pros
- Colgate-Palmolive's revenue increased by over 3% in 2024 to $20.1 billion, showing steady top-line growth.
- The company has a strong dividend yield of approximately 2.7%, providing consistent income to investors.
- Colgate-Palmolive benefits from a diversified product portfolio spanning oral care, personal care, home care, and pet nutrition.
Considerations
- The stock trades at a relatively high price-to-earnings ratio around 21.5, which may indicate overvaluation versus peers.
- Colgate-Palmolive has a higher debt-to-equity ratio that could imply greater financial leverage risks.
- The company's stock price has shown limited appreciation over the past year, suggesting growth limitations in current market conditions.
Pros
- Kimberly-Clark is ranked highly on fundamental stock indicators, reflecting strong financial health and operational performance.
- The company has moderate correlation with Colgate-Palmolive, offering potential portfolio diversification benefits.
- Kimberly-Clark maintains a solid market capitalization near $44 billion, supporting its stable industry position.
Considerations
- Kimberly-Clark’s year-to-date and annual stock performance have been lower compared to Colgate-Palmolive, indicating weaker recent momentum.
- The stock shows moderate beta and volatility, which may lead to higher risk than more defensive consumer staple peers.
- Limited recent growth catalysts have constrained Kimberly-Clark’s ability to outpace competitors in consumer goods.
Colgate-Palmolive (CL) Next Earnings Date
Colgate-Palmolive (CL) is expected to release its next earnings on May 1, 2026, before the market opens. This report will cover the Q1 2026 results, following the prior quarter's release on January 30, 2026. Investors should note the scheduled conference call at 8:30 AM ET on the same day.
Kimberly-Clark (KMB) Next Earnings Date
Kimberly-Clark (KMB) is scheduled to report its Q1 2026 earnings tomorrow, on April 28, 2026, before the market opens. This release will cover the first quarter of 2026, with a conference call at 8:00 AM ET. The prior quarter's results were announced on January 27, 2026, aligning with the company's typical late-January and late-April pattern for quarterly disclosures.
Colgate-Palmolive (CL) Next Earnings Date
Colgate-Palmolive (CL) is expected to release its next earnings on May 1, 2026, before the market opens. This report will cover the Q1 2026 results, following the prior quarter's release on January 30, 2026. Investors should note the scheduled conference call at 8:30 AM ET on the same day.
Kimberly-Clark (KMB) Next Earnings Date
Kimberly-Clark (KMB) is scheduled to report its Q1 2026 earnings tomorrow, on April 28, 2026, before the market opens. This release will cover the first quarter of 2026, with a conference call at 8:00 AM ET. The prior quarter's results were announced on January 27, 2026, aligning with the company's typical late-January and late-April pattern for quarterly disclosures.
Buy CL or KMB in Nemo
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.


